Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Apr;24(4):277-80.
doi: 10.1002/clc.4960240404.

Lessons learned from statin trials

J Auer  1 , R Berent, B Eber
Affiliations
Review

Lessons learned from statin trials

J Auer et al. Clin Cardiol. 2001 Apr.

Abstract

This article aims to review lessons learned about lipid lowering and statins in the past decade and to consider what developments the future may hold. Results from a series of landmark clinical trials confirm that statins significantly reduce cardiovascular morbidity and mortality in patients with and without previous coronary artery disease. The potential of this drug class has yet to be fully explored. Studies currently under way will answer many of the outstanding questions.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers‐Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J, Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl‐coenzyme A reductase and a cholesterol‐lowering agent. Proc Natl Acad Sci USA 1980; 77 (7): 3957–3961 - PMC - PubMed
    1. Slater EE, MacDonald JS: Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 1988; 36 (suppl 3): 72–82 - PubMed
    1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307 - PubMed
    1. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Airforce/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998; 279: 1615–1622 - PubMed
    1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 - PubMed

MeSH terms

Substances